In 2024, Sunny Pharmtech experienced a decline in gross margin to 54%, a 12-percentage point drop compared to the previous year, due to a reduced share of high-margin milestone payments. Coupled with continued R&D investments, operating expenses rose by 8.8%, resulting in an operating loss of NT$162 million and a net loss of NT$156 million for the year. Earnings per share (EPS) stood at a negative NT$1.05.
Read more
